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Abstract 
Several growth factors such as vascular endothelial growth factor (VEGF)-A and placental growth factor (PlGF) 
are involved in the placental vascular development. We investigated whether dysregulation in the VEGF family 
may explain the defective uteroplacental vascularization characterizing preeclampsia. We compared pregnancies 
complicated by early onset severe preeclampsia or intrauterine growth retardation to normal pregnancies. 
Maternal plasma, placentas, and placental bed biopsies were collected. The mRNA levels of VEGF-A, PlGF, and 
their receptors were quantified in placentas and placental beds. Levels of VEGF-A, PlGF, and soluble VEGF 
receptor (VEGFR) were assessed in maternal plasma. In compromised pregnancies, elevated levels of VEGF-A 
and VEGFR-1 mRNAs may reflect the hypoxic status of the placenta. On contrast, the membrane-bound 
VEGFR-1 was decreased in the placental bed of preeclamptic patients. Preeclampsia was associated with low 
levels of circulating PlGF and increased levels of total VEGF-A and soluble VEGFR-1. Free VEGF-A was 
undetectable in maternal blood. Immuno-histochemical studies revealed that VEGF-A and PlGF were localized 
in trophoblastic cells. Altogether, our results suggest two different pathophysiological mechanisms associated 
with preeclampsia. The first one is related to an overproduction of competitive soluble VEGFR-1 that may lead 
to suppression of VEGF-A and PlGF effects. The second one is the down-regulation of its membrane bound 
form (VEGFR-1) in the placental bed, which may result in the defective uteroplacental development. 
Abbreviations: CTR, Internal control; HIF, hypoxia-inducible factor; IUGR, intrauterine growth retardation; 
NRP, neuropilin; PlGF, placental growth factor; sVEGFR-1, soluble form of VEGFR-1; VEGF, vascular 
endothelial growth factor; VEGFR, VEGF receptor. 
 
 
PREECLAMPSIA IS AN important cause of maternal morbidity and mortality and is responsible for more than 
40% of iatrogenic deliveries (1). The underlying pathogenetic mechanisms of this maternal syndrome are much 
debated. Current hypotheses include inflammatory disease, vascular-mediated factors, placental ischemia, 
genetic predisposition, and immune maladaptation (2-5). Preeclampsia is also associated with defective 
uteroplacental vascularization (2). Angiogenesis and vascular transformation of the uteroplacental unit, which 
are crucial to normal fetal development, are impaired (6). However, molecular pathways responsible for normal 
angiogenesis and vascular remodeling in the fetomaternal unit are still poorly understood. Knockout studies 
performed in mice demonstrate the crucial role of vascular endothelial growth factor (VEGF) in embryonic 
development (7-9). Inactivation of a single VEGF gene resulted in embryonic lethality in heterozygous embryos 
at d 11-12, and significant defects in placental vasculature were observed. VEGF seems thus to be involved in 
placental vascular development (10). 
VEGF-A is one of the most important growth factors for endothelium. It induces angiogenesis and endothelial 
cell proliferation and plays an important role in regulating vas-culogenesis (11, 12). Other proteins are related in 
structure and receptor specificity to VEGF-A. The VEGF family consists of VEGF-A, VEGF-B, VEGF-C, 
VEGF-D, VEGF-E, and placental growth factor (PlGF) (13). There are several splice variants of VEGF-A. The 
major ones include 121, 165, 189, and 206 amino acids, each comprising a specific exon addition. VEGF 165 is 
the most predominant protein. The 165,189, and 206 amino acids splice variants have heparin-binding domains, 
which are involved in presentation to VEGF receptors (VEGFRs). PlGF is a member of the VEGF family closely 
related to VEGF-A (10). 
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VEGF-A transcription is potentiated in response to hypoxia and by activated oncogenes (14). Hypoxia-inducible 
factor (HIF)-1 is a transcriptional complex that plays a central role in oxygen homeostasis. HIF binds to hypoxia 
response elements of the VEGF-A gene as a heterodimer of proteins designated HIF-1α and HIF-1β subunits 
(15). HIF-1α sub-units are specific to the response to hypoxia, whereas HIF-1β subunits are constitutive nuclear 
proteins (16). In normoxia, HIF-1α subunits are rapidly destroyed by the ubiquitous proteasome pathway such 
that the transcription complex cannot form (17, 18). Recent studies have shown that degradation of HIF-1α is 
secondary to its recognition by the von Hippel Lindau tumor suppressor protein. Interactions between HIF-1α 
and von Hippel Lindau tumor suppressor protein are regulated through enzymatic hydroxylation (17). In hypoxia 
this process is suppressed and HIF heterodimers activate the transcription of the VEGF-A gene (16). On the 
contrary, PlGF expression is not up-regulated by hypoxia (19). 
There are two main receptors for VEGF-A and PLGF, VEGFR-1 (also known as Flt-1) and VEGFR-2, (also 
known as KDR or flk-1) (10, 20). They have the common properties of multiple IgG-like extracellular domains 
and tyrosine kinase activity. Both VEGFR-1 and VEGFR-2 are essential for development of the embryonic 
vasculature in mice (21). They have different transduction properties. VEGFR-2 undergoes strong ligand-
dependent tyrosine phosphorylation and mediates mitogenesis and chemotaxis in response to VEGF, whereas 
VEGFR-1 reveals weak responses. Because VEGFR-1 has strong affinity to VEGF and its kinase activity is 
weak, the regulatory role of VEGFR-1 appears to be due to VEGF-trapping activity (13, 22). The tyrosine kinase 
domain of VEGFR-1 is implicated in inhibition of VEGF-dependent endothelial cell migration (23). VEGFR-1 is 
expressed by trophoblast cells and thought to play a physiological function during pregnancy (24,25). A soluble 
form of VEGFR-1 (sVEGFR-1) can be detected in peripheral blood. Soluble VEGFR-1 has a strong antagonistic 
activity and neutralizes the effects mediated by VEGF and PlGF effects (26-28). It is known that villous and 
extravillous trophoblastic cells produce sVEGFR-1 (29). 
 
Table 1. Clinical characteristics of the study subjects 
 SPE IUGR Control 
n 19 10 31 
Age [mean (yr)] 30 34 30 
Gravida/paragravida (mean) 2/1 2/0 2/1 
BP (mm Hg) (systolic/diastolic) 180/110a 128/79 109/77 
Gestational age (wk) 30.5a 32.2a 38.3 
Birth weight (g) 1,250a 1,300a 3,064 
Placental weight (g) 327a 316a 582 
Abnormal OD 7 (36%) 7 (70%) 0 
OD = 0 and RDF 4 (21%) 4 (20%) 0 
Proteinuria > 3 g/24 h 10 (52%) 0 0 
Platelets 154,000a 216,000 230,000 
BP, Blood pressure; OD, ombilical doppler; SPE, severe preeclampsia; RDF, reverse diastolic flow. 
a P < 0.05 compared to control group. 
 
VEGF-A and PlGF are implicated in several pathological conditions associated with enhanced angiogenesis such 
diabetic retinopathy, carcinogenesis, rheumatoid arthritis, and wound repair (30). In preeclampsia and some 
cases of fetal growth restriction, deficient uteroplacental angiogenesis is usually reported, leading to the classic 
notion of "placental hypoxia" in these two disorders (31, 32). Recently the idea of placental hypoxia has been 
challenged, especially in cases of severe early-onset growth-restricted pregnancies with absent or reverse end-
diastolic flow velocity in the umbilical artery. It is supposed that in such cases, oxygen transport to the fetal 
blood is compromised because of reduced villous placental angiogenesis resulting in hyperoxic status of 
maternal blood in the intervillous space (33, 34). Several studies (35-41) aimed to analyze the expression of 
VEGF-A in such pathological conditions during pregnancy but results are conflicting, some authors reporting 
reduced levels of VEGF-A in maternal circulation and others showing increased levels of VEGF-A in maternal 
circulation, compared with normal pregnancies. The aim of this study was therefore to attempt to explain the 
discrepancies between the results of the available studies. We analyzed modifications in pregnancies complicated 
by preeclampsia or intrauterine growth retardation (IUGR) of VEGF-A family members in the placenta, uterus, 
and maternal blood. 
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Table 2. Sequence of primers and TaqMan probes used for RT-PCR studies 
Gene 
(accession no.) 
Position Sequence Size 
PCR 
product 
Cycles  (no. of 
PCR amplifications) 
   479 bp  
VEGF-FP 1208F 5 ' - CCTGGTGGACATCTTCCAGGAGTA- 3 ' 407 bp 33 
VEGF-RP 
(AH001553) 
1687R 5 ' - CTCACCGCCTCGGCTTGTCACA- 3 ' 347 bp  
28S rRNA-FP 12403F 5 ' - GTTCACCCACTAATAGGGAACGTGA- 3 ' 275 bp 19 
28S rRNA-RP 
(U13369) 
12614R 5 ' - GATTCTGACTTAGAGGCGTTCAGT - 3 ' 212 bp  
VEGFR1-FP 2438F 5 ' - TCCCTTATGATGCCAGCAAGT - 3 ' 79 bp 40 
VEGFR1-RP 2516R 5 ' - CCAAAAGCCCCTCTTCCAA-3 '   
VEGFR1 Probe 
(AF063657) 
2469 5 ' - CCGGGAGAGACTTAAACTGGGCAAATCA- 3 '   
sVEGFRl-FP 2209F 5 ' - ACAATCAGAGGTGAGCACTGCAA- 3 ' 180 bp 40 
sVEGFRl-RP 2388R 5 ' - TCCGAGCCTGAAAGTTAGCAA- 3 '   
sVEGFRl Probe 
(U01134) 
2257 5 ' - 
TCCAAATTTAAAAGCACAAGGAATGATTGTACC
AC - 3 ' 
  
VEGFR2-FP 791F 5 ' - CTTCGAAGCATCAGCATAAGAAACT - 3 ' 156 bp 40 
VEGFR2-RP 946R 5 ' - TGGTCATCAGCCCACTGGAT - 3 '   
VEGFR2 Probe 
(AF063658) 
820 5 ' - AACCGAGACCTAAAAACCCAGTCTGGGAGT 
- 3 ' 
  
PlGF-FP 668F 5 ' - CCTACGTGGAGCTGACGTTCT - 3 ' 77 bp 40 
PlGF-RP 744R 5 ' -TCCTTTCCGGCTTCATCTTCT- 3 '   
PlGF Probe 
(X54936) 
702 5 ' -CTGCGAATGCCGGCCTCTGC- 3 '   
NRP1-FP 1831F 5 ' - CACAGTGGAACAGGTGATGACTTC - 3 ' 112 bp 40 
NRP1-RP 1942R 5 ' - AACCATATGTTGGAAACTCTGATTGT - 3 '   
NRP1 Probe  
(XM 034725) 
1883 5 ' - CCACAGAAAAGCCCACGGTCATAGACA- 3 '   
 
MATERIALS AND METHODS 
Sample collection 
Samples were collected from 60 pregnant women recruited between January 1999 and December 2001 from the 
department of Obstetrics and Gynecology at the hospital La Citadelle, Liège, Belgium. The protocol for this 
study was approved by the local ethics committee, and informed consent was obtained from the patients. 
Nineteen subjects had severe preeclampsia, defined using the criteria of hypertension, edema, and proteinuria 
defined as below. Hypertension was defined as systolic and diastolic blood pressures above 160 mm Hg and 100 
mm Hg, respectively, in at least two consecutive measurements. Proteinuria was defined as more than 1000 mg 
per 24 h collection or at least 3+ on urine sample when urine could not be collected for 24h. 
Ten subjects had IUGR defined as birth weight below the third centile according to gestational age. None of 
these patients had hypertension or proteinuria. Thirty-one patients had noncomplicated pregnancy and 
constituted the control group. Nineteen patients from the control group were recruited just before planned 
cesarean delivery and 12 were enrolled in the study at their seventh-month visit to obtain a control group match 
for gestational age for plasma measurements. None of the patients had chronic hypertension or renal or 
endocrine disease. 
Placenta samples, placental bed samples, and maternal plasma were collected during cesarean section. None of 
the patients were in labor. After extraction of the newborn, placental insertion was verified and the placenta was 
rapidly delivered. Basal plate was removed from the placenta. Placenta villi were collected in the center part of 
the placenta avoiding infarcted areas. Placental bed biopsies were performed in the uterine wall as close as 
possible to the center part of the implantation site. All blood samples were centrifuged at 3000 rpm during 20 
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min at 4 C. Aliquots of plasma were stored at -80 C until analysis. Tissue samples were frozen in liquid nitrogen 
within 30 min after birth and stored at -20 C until analysis. Clinical details of the patients are presented in Table 
1. 
Fig. 1. VEGF-A mRNA isoforms in placentas and placental beds. Representative aspect of multiples RT-PCR for 
VEGF189, VEGF165, VEGF145, VEGF121 isoforms in placentas (A) and placental beds (C). Quantification of 
VEGF mRNA levels performed by end point quantitative RT-PCR is shown for placentas (B) and placental beds 




RNA extraction. The frozen tissues were pulverized using a Dismem-brator (B. Braun Biotech International, 
Gmbh Melsungen, Germany) and suspended in lysis buffer (5 M guanidine thiocyanate, 25 mM sodium citrate, 
17mM N-lauroylsarcosine and 0.1 M 2-mercaptoethanol, pH 7.0). Total RNA was purified by cesium chloride 
ultracentrifugation according to the procedure of Chirgwin et al. (42). 
Primers 
Primers pairs used in this study are described in Table 2. Primers for the VEGF-A gene were chosen to 
distinguish among VEGF189, VEGF165, VEGF145, and VEGF121 mRNA isoforms. Intron-spanning primers and 
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probes for the TaqMan system (primers for VEGFR-1 (Flt-1), sVEGFR-1, VEGFR-2 (KDR/Flk-1), PlGF, and 
neuropilin (NRP)l were designed to meet specific criteria by using Primer Express software (Perkin-Elmer, 
Foster City, CA). All primers were synthesized by Eurogentec (Liège, Belgium). The 5'- and 3'-end nucleotides 
of the probe were labeled with a reporter (FAM = 6-carboxy-fluorescein) and a quencher dye (TAMRA =                
6-carboxy-tetramethylrhodamine). We conducted BLASTn (National Center for Biotechnology Information, 
Bethesda, MD) searches against dbEST and the nonredundant set of GenBank, EMBL, and DDBJ database 
sequences to confirm the total gene specificity of the nucleotide sequences chosen for the primers. The 18S 
rRNA was measured using the Pre-Developped TaqMan assay reagents endogenous control kit (PE Applied 
Biosystems, Inc., Foster City, CA). 
End point quantitative RT-PCR for VEGF-A mRNA isoforms 
VEGF189, VEGF165, VEGF145, and VEGF121 mRNA isoforms and 28S rRNA were measured in 10-ng aliquots of 
total RNA using the GeneAmp Thermostable rTth reverse transcriptase RNA PCR kit (Applied Biosystems) and 
two pairs of primers (Table 2). The efficiency of the RT-PCR was monitored with an internal control (CTR) as 
previously described (43). RT-PCR products were resolved on 10% acrylamide gels and analyzed using a Fluor-
S MultiImager (Bio-Rad Laboratories, Hercules, CÀ) after staining with Gelstar dye (FMC BioProducts, 
Rockland, ME). The expected size for VEGF189, VEGF165, and VEGF121 is, respectively, 479, 407, 347, and 275 
bp and 212 bp for 28S rRNA. 
Ratios VEGF:CTR and 28S:CTR were determined. VEGF mRNA levels were expressed as the ratio of VEGF 
transcripts:28S transcripts. 
 
Table 3. mRNA levels (arbitrary units) of VEGF, PlGF, and their receptors in the placenta 





VEGF SPE 1.21 0.42 1.57 0.01 
 IUGR 0.83 0.59 1.34 0.006 
 Control 0.4 0.29 0.62  
PlGF SPE 0.38 0.33 0.65 0.34 
 IUGR 0.47 0.34 0.77 0.15 
 Control 0.47 0.34 0.78  
VEGFR-1 SPE 1.16 0.49 1.87 0.0002 
 IUGR 0.49 0.31 1.35 0.04 
 Control 0.31 0.26 0.48  
VEGFR-2 SPE 0.31 0.18 0.44 0.47 
 IUGR 0.17 0.12 0.27 0.03 
 Control 0.27 0.22 0.4  
SVEGFR-1 SPE 0.41 0.18 0.94 0.0002 
 IUGR 0.23 0.12 0.52 0.0019 
 Control 0.08 0.06 0.12  
NRP SPE 0.47 0.27 0.33 0.73 
 IUGR 0.5 0.26 0.76 0.72 
 Control 0.51 0.33 0.67  
SPE, Severe preeclampsia. 
a P value for comparison us. the control group. 
 
Real-time quantitative RT-PCR VEGFR-1, sVEGFR-1, VEGFR-2, PlGF, and NRP1 mRNA 
Real-time quantitative RT-PCR analyses for VEGFR-1 (Flt-1), sVEGFR-1 (sFlt-1), VEGFR-2 (KDR/Flk-1), 
PIGF, NRP1 mRNAs, and 18S rRNA were performed using the ABI PRISM 7700 sequence detection system 
instrument and software (PE Applied Biosystems). The sequences of the PCR primer pairs and fluorogenic 
probes that were used for each gene are shown in Table 2. The relative quantitation of our data has been 
performed using the standard curve method according to the manufacturer recommendation (PE Applied 
Biosystems in User Bulletin #2). The relative expression level of the gene of interest was computed with respect 
to 18S rRNA to normalize for variation in the quality of RNA and the amount of input cDNA. For each 
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experimental sample, the amount of target was determined from a standard curve. The latter was constructed 
with 5-fold serial dilutions of pooled placenta cDNA (50,000 ng to 80 ng) and was run in duplicate during every 
experiment. The cycle threshold obtained for each amount of pooled placenta cDNA allowed to draw a linear 
standard curve of amplification for each target gene. The cycle threshold of any given sample was reported to 
this standard curve both for the 18S RNÀ and each mRNA. The amount of target gene was divided by the 18S 
rRNA amount to obtain a normalized target value (as described by the manufacturer PE Applied Biosystems in 
User Bulletin #2). PCR was performed with the TaqMan Universal PCR Master Mix (PE Applied Biosystems) 
using 5 µl diluted cDNA (equivalent to 10 ng total RNA), 200 nM of the probe, and 400-nM primers in a 25-µl 
final reaction mixture. After a 2-min incubation at 50 C to allow for uracil-N-glycosylase cleavage, AmpliTaq 
Gold was activated by an incubation for 10 min at 95 C. Each of the 40 PCR cycles consisted of 15 sec of 
denaturation at 95 C and hybridization of probe and primers for 1 min at 60 C. 
To confirm amplification specificity, the PCR products were also examined by subsequent 2% agarose gel 
electrophoresis. Experiments were repeated at least three times in duplicate. 
Immunoassays 
Levels of free VEGF-A and free PIGF in maternal plasma were measured by the sandwich enzyme immunoassay 
technique (R&D Systems Europe Ltd., Abington, UK). Total VEGF-A (free and bound VEGF-A) in maternal 
plasma were measured by competitive enzyme immunoassay (Cytimmune, College Park, MD). Levels of the 
soluble form of VEGF-R1 in maternal plasma were measured by sandwich enzyme immunoassay technique 
(Bender MedSytems, Vienna, Austria). All sam-ples were measured in duplicate. Sensitivity for free VEGF, free 
PlGF, total VEGF, and sVEGF-Rl are, respectively, 9 pg/ml, 7 pg/ml, 0.2 ng/ml, and 0.1 ng/ml. 
Fig. 2. mRNA levels of VEGF, PIGF, and their receptors in placentas. All RNA quantifications were performed 
by real time RT-PCR except for VEGF mRNA isoforms. Levels of mRNA are expressed as arbitrary units (A.U.). 
SPE, Severe preeclampsia. * , P < 0.05. 
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Table 4. mRNA levels (arbitrary units) of VEGF, PlGF, and their receptors in the placental bed 





VEGF SPE 3.03 1.75 4.15 0.12 
 IUGR 3.47 2.89 5.1 0.5 
 Control 3.62 2.79 4.12  
PlGF SPE 0.015 0.01 0.022 0.29 
 IUGR 0.007 0.003 0.01 0.04 
 Control 0.012 0.006 0.041  
VEGFR-1 SPE 0.06 0.04 0.1 0.0003 
 IUGR 0.08 0.04 0.14 0.01 
 Control 0.14 0.09 0.19  
VEGFR-2 SPE 0.27 0.12 0.59 0.22 
 IUGR 0.26 0.22 0.48 0.4 
 Control 0.34 0.22 0.43  
SVEGFR-1 SPE 0.01 0.007 0.038 0.88 
 IUGR 0.009 0.0035 0.034 0.5 
 Control 0.01 0.007 0.021  
NRP SPE 0.34 0.21 0.69 0.93 
 IUGR 0.28 0.23 0.68 0.85 
 Control 0.35 0.25 0.5  
SPE, Severe preeclampsia. 
a P value for comparison us. the control group. 
 
Immunohistochemistry (VEGF-A and PlGF) 
Placentas were fixed in 4% formalin for 4-12 h and then embedded in paraffin. Paraffin sections (4 µm) were 
mounted on aminopropyl-triethoxysilane (Tespa)-coated glass slides. 
Sections were dewaxed in xylene and rehydrated. Nonspecific antibody-binding was blocked by incubation for 
20 min in a blocking reagent containing 3% H2O2 and for 60 min in 10% serum albumin solution. Then 4 µg/ml 
VEGF-A antibody (rabbit antihuman VEGF (A-20), Santa Cruz Biotechnology, Heidelberg, Germany), 50 µg/ml 
PIGF antibody (mouse monoclonal antihuman PIGF, R&D Systems, MAB264) and 4 µg/ml cytokeratin 
antibody (mouse antihuman CK-07, DakoCytomation, Glostrup, Denmark) were incubated with the sections for 
1 h at room temperature. Sections were washed in Tris-buffered saline-0.1% Tween 20 and incubated with a 
secondary antibody peroxidase conjugated (goat antimouse Envision, Dako K 4000, DakoCytomation) and goat 
antirabbit Envision (Dako K 4003) was applied for 30 min. Staining was detected with the diamino-benzidine 
chromogen after 5 min. Nuclei were counterstained by incubation for 2 min with hematoxylin. Sections were 
mounted, examined, and photographed under a Leica-DMLS microscope (Leica Microsystems, Wetzlar, 
Germany) couple to a digital camera (Nikon Coolpix 990, Nikon Instruments Europe, Badhoevedorp, The 
Netherlands). Controls were performed by omitting the primary antibody or by incubating the sections with 
nonspecific IgG at the same concentration as the primary antibody. 
Statistics 
Comparisons between the different groups were made with the Kruskall-Wallis test, and significant differences 
were further analyzed by pairwise comparison with the Mann-Whitney U test. Results are shown as median ± 
quartiles (25th-75th centile). P < 0.05 were considered statistically significant. 
RESULTS 
mRNA quantification in placentas 
The three main isoforms (121, 165, 189) of VEGF-A were expressed in the placenta, isoform 121 being 
predominant (Fig. 1A; values for the median and quartiles are detailed in Table 3). mRNA levels of VEGF-A 
isoforms were significantly higher in pregnancies complicated by preeclampsia and IUGR, compared with 
controls (Fig. 1B). Similarly, total VEGF-A mRNA levels (sum of the three isoforms) were higher in placentas 
from preeclamptic patients and patients with IUGR, compared with controls (Fig. 2). There was no difference in 
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PIGF mRNAs among the three groups. VEGFR-1 mRNA and sVEGFR-1 mRNA levels were significantly 
increased in placentas from preeclamptic patients, compared with normal pregnancies (Fig. 2). On the contrary, 
no significant difference was found among the three groups for VEGFR-2 mRNAs and NRP mRNAs. 
 
Fig. 3. mRNA levels of VEGF, PIGF, and their receptors in placental beds. All RNA quantifications were 
performed by realtime RT-PCR except for VEGF mRNA iso-forms. Levels of mRNA are expressed as arbitrary 
units (A.U.). SPE, Severe preeclampsia. *, P < 0.05. 
 
 
mRNA quantification in placental beds 
VEGF 121, VEGF 165, and VEGF 189 mRNAs were expressed in the placental bed (Fig. 1C; values for the 
median and quartiles are detailed in Table 4). The isoform 121 was again the predominant one (Fig. 1D). Levels 
of VEGF, PlGF, sVEGFR-1, VEGFR-2, and NRP mRNAs were similar in samples from preeclamptic patients 
and normal pregnancies (Fig. 3). When considering VEGF isoforms, no significant difference was detected 
between both groups (Fig. 1). Compared with controls, VEGFR-1 mRNA expression was significantly decreased 
in preeclamptic patients and patients with IUGR. Although the levels of PlGF mRNA were decreased in the 
IUGR group in comparison with controls, the difference did not reach significance (Fig. 3). 
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VEGF-A measurements in maternal plasma 
Free VEGF-A was below the detection limit (9 pg/ml) in 80% of the samples (Fig. 4). Compared with 
uncomplicated pregnancies, total VEGF-A (free + bound VEGF-A) was significantly higher in the plasma from 
preeclamptic patients [25.24 (21.22-42.92) vs. 6.83 (5.32-8.94) ng/ml, P < 0.0001] and patients with IUGR 
[22.67 (15.93-30.03) vs. 6.83 (5.32-8.94) ng/ml, P < 0.0001] (Fig. 4). There was no difference in VEGF-A levels 
between controls at term during cesarean section and controls matched for gestational age [6.67 (4.32-8.91) vs. 
6.83 (5.32-8.94) ng/ml, P = 0.5]. 
Compared with uncomplicated pregnancies, free PlGF was significantly lower in the plasma from preeclamptic 
patients [67.41 (57.1-118.5) vs. 585.9 (356-1011) pg/ml, P < 0.0001] and patients with IUGR [101.5 (60.65-
145.3) vs. 585.9 (356-1011) pg/ml, P < 0.0001] (Fig. 4). Similar PlGF levels were observed in controls at term 
during cesarean section and in controls matched for gestational age [344.3 (210.8-735.2) vs. 585.9 (356-1011) 
pg/ml, P = 0.2]. 
Soluble VEGFR-A levels were significantly higher in the plasma from preeclamptic patients [2.69 (2.31-2.97) 
vs. 0.12 (0-0.29) ng/ml, P < 0.0001] and patients with IUGR [1.81 (0.82-2.76) vs. 0.12 (0-0.29) ng/ml, P < 
0.0001], compared with uncomplicated pregnancies (Fig. 4). Moreover, sVEGFR-1 levels were lower in the 
control group matched for gestational age than in the control group at term [0.12 (0-0.29) vs. 0.66 (0.41-0.93) 
ng/ml, P = 0.002]. 
 
Fig. 4. Levels of total VEGF, free PlGF, and sVEGFR-1 in maternal plasma. Quantification of total VEGF, free 
PlGF, and sVEGFR-1 in maternal plasma from patients with IUGR, severe preeclampsia (SPE), and 
uncomplicated pregnancies matched for gestational age (matched control group). Patients with uncomplicated 
pregnancy at term are represented as control group. *, P < 0.05. 
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Immunolocalization of VEGF and PlGF in the placenta 
Cells producing VEGF-A and PlGF in the placenta were identified by immunohistochemistry. VEGF-A (Fig. 5, 
A and B) and PlGF (Fig. 5, C and D) are produced by villous cy-totrophoblast, syncytiotrophoblast, and 
extravillous tro-phoblast. Cytokeratin was used to localize cytotrophoblasts (Fig. 5F). Negative controls are 
illustrated in Fig. 5F. 
DISCUSSION 
In the present study, we have shown an important dys-regulation of the expression of VEGF, PlGF, and their 
receptors by the placenta in pregnancies complicated by severe early-onset preeclampsia  or  IUGR.  VEGF-A, 
PlGF, and VEGFR-1 are produced by villous and extravillous trophoblastic cells. VEGF-A, VEGFR-1, and 
sVEGFR-1 were significantly up-regulated in placentas from preeclamptic women and patients with IUGR, 
whereas no modification was found for PlGF, VEGFR-2, or NRP. High levels of VEGF, VEGFR-1, and 
sVEGFR-1 in preeclampsia are probably related to the hypoxic status of the placenta (44). We found the same 
increase of expression of VEGF, VEGFR-1, and sVEGFR-1 in placentas from pregnancies complicated by early-
onset IUGR, suggesting that in these cases the placenta may also be hypoxic. It has been postulated that in severe 
IUGR with absent or reverse end-diastolic flow velocity in the uterine artery, the transfer of oxygen across the 
placenta from the maternal to the fetal circulation may be reduced, leading to a hyperoxic placenta and hypoxic 
fetus (33, 34). Our results do not support this hypothesis, but only 20% of our patients had absent or reverse end-
diastolic flow velocity in the uterine artery. 
VEGF, PlGF, and sVEGFR-1 produced by the placenta are released in maternal circulation. We therefore 
investigated whether the levels of these angiogenic factors were increased or decreased in maternal plasma 
because this information is conflicting in the literature (36-41). We chose to assess the expression of these 
factors in maternal plasma rather than maternal serum as suggested in the literature (45). Serum levels of VEGF 
are higher than those found in the plasma. The difference between plasma and serum concentrations have been 
ascribed to the release of VEGF from platelets and other blood cells during clotting (45). We used different 
assays to differentiate free circulating VEGF (capture immunoassay) to the VEGF bound to circulating proteins 
such as sVEGFR-1 or α-macroglobulin (competitive immunoassay). We found that free VEGF was undetectable 
in most samples. These results are consistent with data from Vuorela et al. (36). On the contrary, total circulating 
VEGF was detectable in all samples. Levels of total VEGF were significantly higher in preeclampsia and 
pregnancies with IUGR, compared with normal pregnancies at term or matched for gestational age. These results 
are similar to those previously reported by Kupferminc et al. (39) and Sharkey et al. (37). Free PlGF was found 
to be significantly lower, whereas sVEGFR-1 was significantly higher in preeclampsia and pregnancies with 
IUGR, compared with normal pregnancies at term or matched for gestational age. These results are in 
concordance with recent studies showing elevated levels of sVEGFR-1 in preeclampsia (46, 47). 
Three studies (35, 36, 38) reported measurements of free VEGF with the same technique as ours, but all samples 
were maternal serum. In these studies, free VEGF was detectable and decreased in preeclampsia, compared with 
normal pregnancies. Other studies reported measurements of total VEGF in maternal serum (41) or maternal 
plasma (37, 39) and showed a significant increased in preeclampsia, compared with normal pregnancies. Here 
we show a parallel increase of total VEGF and sVEGFR-1 in preeclampsia, compared with normal pregnancy. It 
seems that during pregnancy most of the circulating VEGF is bound to sVEGFR-1 produced in high amounts by 
the placenta. During preeclampsia placental production of VEGFR-1 and sVEGFR-1 is increased probably 
because of the hypoxic status of the placenta. This increase of sVEGR-1 in preeclampsia explains discrepancies 
between studies in the literature. Compared with normal pregnancies, levels of free VEGF (circulating at 
concentrations around 2-10 pg/ml) are lower, whereas levels of total VEGF (circulating at concentrations around 
20 ng/ml) are higher in maternal circulation from preeclamptic patients, compared with controls. 
Levels of circulating PlGF (circulating at concentrations around 400 pg/ml) are lower in preeclampsia than in 
normal pregnancies. This difference may be attributed to the fact that PlGF is also bound to sVEGFR-1 in 
maternal circulation. In this study, we show that the depressed concentrations of free VEGF and free PlGF in 
preeclampsia are due to an excessive production of sVEGFR-1, as suggested by Lyall (38) and Maynard et al. 
(46). In their recent study, Maynard et al. (46) have shown in a rodent model that VEGF, PlGF, and sVEGFR-1 
are likely to play a role in the pathogenesis of preeclampsia. Excess placental production of sVEGFR-1 
contributes to hypertension, proteinuria, and glomerular endo-theliosis. Recently Koga et al. (47) reported that 
concentrations of sVEGFR-1 in serum from women with preeclampsia were more than 6-fold higher than those 
from control. Er-emina et al. (48) provided additional evidence for a critical role of VEGF in renal disease 
during preeclampsia. In this study, mice lacking one VEGF allele in renal podocytes developed a renal disease, 
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characterized by proteinuria and endotheliosis, the renal lesion seen in preeclampsia. 
Results from the placental bed biopsies show no differences between the study groups for the expression of 
VEGF, PlGF, VEGFR-2, and NRP, whereas VEGFR-1 expression was significantly reduced in patients with 
preeclampsia (VEGFR-1 expression was reduced in the IUGR group but not significantly). Although it is not 
possible to determine whether this modification is cause or consequence of the pathologic status of the 
pregnancy, low levels of VEGFR-1 in the placental bed may explain the defective uterine vascularization 
frequently associated with early-onset preeclampsia. Altogether our study indicates the involvement of sVEGFR-
1 as an antagonist to VEGF and PlGF in preeclampsia. The down-regulation of the membrane-bound form of 
VEGFR-1 in the placental bed may also result in the decreased maternal vascular adaptation to pregnancy. 
 
Fig. 5. Immunolocalization of VEGF and PlGF in the placenta. Immunolocalization of VEGF in the villi (V) and 
basal plate (BP) (A, magnification x 20; B, magnification x 60). Immunolocalization of PlGF in the V and BP (C, 
magnification x 20; D, magnification x 60). Immunolocalization of cytokera-tin (CK) in the V and BP (E, 
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